KRYS · Krystal Biotech, Inc.
$332.27
+3.93 (+1.20%)
At close · Aug 14
Market Cap
$9.83B
Shares
29.60M
Krystal Biotech, Inc. Earnings Call Transcripts
Every quarterly earnings call for Krystal Biotech, Inc. (KRYS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$8.56M
$80.75M
'23 Q3
23-11-06
·
$42.14M
$8.69M
'23 Q4
24-02-26
·
$45.25M
$932,000
'24 Q1
24-05-06
·
$70.28M
$15.57M
'24 Q2
24-08-05
▲879.9%
$83.84M
$27.18M
'24 Q3
24-11-04
▲116.3%
$91.14M
$45.48M
'24 Q4
24-12-31
▲94.9%
$88.18M
$35.73M
'25 Q1
25-05-06
▲36.6%
$96.04M
$38.33M
'25 Q2
25-08-04
▲16.6%
$97.80M
$79.36M
'25 Q3
25-11-03
▲17.5%
$107.11M
$51.40M
'25 Q4
26-02-17
▲31.9%
$116.36M
$55.93M
'26 Q1
26-05-04
LATEST
▲24.1%
$119.22M
$54.77M
'26 Q2
26-08-03
Earnings call
FY26 · Q2
2026-08-03
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
Confident tone
International Vyjuvec launch momentum
U.S. commercial performance and penetration
Pricing and reimbursement negotiations
Revenue
$119.22M
▲ 24.1% YoY Diluted EPS
$1.79
▲ 38.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-04
First Quarter 2026 Earnings Call
Confident tone
Pricing and reimbursement negotiations in Europe
Vyjuvec U.S. commercial performance
Oncology program KB803
Revenue
$116.36M
▲ 31.9% YoY Diluted EPS
$1.83
▲ 52.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-17
Krystal Biotech, Inc. Q4 FY2025 Earnings Call
Confident tone
Geographic Expansion
VYJUVEC Commercial Performance
Ophthalmology / Ocular Program Dosing Changes
Revenue
$107.11M*
▲ 17.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Krystal Biotech, Inc. Q3 FY2025 Earnings Call
Confident tone
Geographic expansion (Europe and Japan)
VYJUVEK commercial launch momentum
Pipeline development and clinical readouts
Revenue
$97.80M
▲ 16.6% YoY Diluted EPS
$2.66
▲ 192.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Krystal Biotech, Inc. Q2 FY2025 Earnings Call
Confident tone
Vyjuvec launch and U.S. commercial progress
Patient compliance dynamics
Aesthetics / KB304 / Jun subsidiary
Revenue
$96.04M
▲ 36.6% YoY Diluted EPS
$1.29
▲ 143.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Krystal Biotech, Inc. Q1 FY2025 Earnings Call
Confident tone
VYJUVEK U.S. commercial performance
VYJUVEK global expansion (EU/Japan)
Clinical pipeline readouts in 2025
Revenue
$88.18M
▲ 94.9% YoY Diluted EPS
$1.20
▲ 3900% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Krystal Biotech, Inc. Q4 FY2024 Earnings Call
Confident tone
VYJUVEK U.S. launch
Lung delivery platform pipeline
Ophthalmology (B-VEC for DEB eye lesions)
Revenue
$91.14M*
▲ 116.3% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Krystal Biotech, Inc. Q3 FY2024 Earnings Call
Confident tone
VYJUVEK launch and revenue
Ex-U.S. launches and reimbursement
Clinical pipeline readouts
Revenue
$83.84M
▲ 879.9% YoY Diluted EPS
$0.91
▼ 67.4% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Krystal Biotech, Inc. Q2 FY2024 Earnings Call
Revenue
$70.28M
Diluted EPS
$0.53
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Krystal Biotech, Inc. Q1 FY2024 Earnings Call
Confident tone
Patient Compliance and Real-World Experience
VYJUVEK U.S. Commercial Launch
International Expansion
Revenue
$45.25M
Diluted EPS
$0.03
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Krystal Biotech, Inc. Q4 FY2023 Earnings Call
Confident tone
VYJUVEK US launch trajectory and revenue
Reimbursement, J-code and gross-to-net dynamics
Pipeline and platform breadth
Revenue
$42.14M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Krystal Biotech, Inc. Q3 FY2023 Earnings Call
Revenue
$8.56M
Diluted EPS
$2.79
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts
CIK
1711279
CUSIP
501147102
13F (30d)
393 filings
392 filers
Visit website
Investor relations